FDA
-
-
-
-
-
-
-
Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
Sana Biotechnology (SANA) PT Lowered to $8 at H.C. Wainwright
-
-
-
-
-
-
-
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
-
-
-
-
-
-
-
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
-
-
-
-
-
-
-
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
-
-
-
-
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

